Anika Therapeutics (ANIK) EBT (2016 - 2025)
Historic EBT for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$2.2 million.
- Anika Therapeutics' EBT fell 78800.0% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.3 million, marking a year-over-year decrease of 15048.05%. This contributed to the annual value of -$4.1 million for FY2024, which is 22921.42% down from last year.
- Anika Therapeutics' EBT amounted to -$2.2 million in Q3 2025, which was down 78800.0% from -$4.0 million recorded in Q2 2025.
- Anika Therapeutics' EBT's 5-year high stood at $25.3 million during Q4 2023, with a 5-year trough of -$12.0 million in Q1 2023.
- In the last 5 years, Anika Therapeutics' EBT had a median value of -$2.2 million in 2025 and averaged -$90157.9.
- Its EBT has fluctuated over the past 5 years, first skyrocketed by 35115.19% in 2022, then plummeted by 78800.0% in 2025.
- Anika Therapeutics' EBT (Quarter) stood at -$6.6 million in 2021, then surged by 351.15% to $16.7 million in 2022, then skyrocketed by 51.56% to $25.3 million in 2023, then tumbled by 105.04% to -$1.3 million in 2024, then tumbled by 75.37% to -$2.2 million in 2025.
- Its last three reported values are -$2.2 million in Q3 2025, -$4.0 million for Q2 2025, and -$3.9 million during Q1 2025.